The belief that a depression of cardiac contractility is thefundamental defect in patients with chronic heart failure hasled to the development during the past 20 years of nearly 100new drugs with positive inotropic activity. Although all theseagents exert favorable hemodynamic effects, none have producedconsistent improvement in symptoms or exercise tolerance, andmany have shortened the survival of patients with heart failure1,2.Questions about efficacy and safety have surfaced regardlessof the drug's mechanism of action, but there has been particularconcern about agents that act by inhibiting cyclic AMP phosphodiesterase(e.g., milrinone)2. Given . . . [Full Text of this Article]
References
Related Letters:
Vesnarinone for Heart Failure
Swedberg K., Wedel H., Neely D., Schwartz A., Feldman A. M., Bristow M. R., Parmley W. W., Packer M.
Extract |
Full Text
N Engl J Med 1994;
330:64-66, Jan 6, 1994.
Correspondence
This article has been cited by other articles:
De Luca, L., Colucci, W. S., Nieminen, M. S., Massie, B. M., Gheorghiade, M.
(2006). Evidence-based use of levosimendan in different clinical settings. Eur Heart J
27: 1908-1920
[Abstract][Full Text]
Tokuda, Y., Grant, P. W., Wolfenden, H. D., Manganas, C., Lyon, W. J., Murala, J. S.K.
(2006). Levosimendan for patients with impaired left ventricular function undergoing cardiac surgery. ICVTS
5: 322-326
[Abstract][Full Text]
Michaels, A. D., McKeown, B., Kostal, M., Vakharia, K. T., Jordan, M. V., Gerber, I. L., Foster, E., Chatterjee, K.
(2005). Effects of Intravenous Levosimendan on Human Coronary Vasomotor Regulation, Left Ventricular Wall Stress, and Myocardial Oxygen Uptake. Circulation
111: 1504-1509
[Abstract][Full Text]
Deswal, A., Petersen, N. J., Feldman, A. M., White, B. G., Mann, D. L.
(2001). Effects of Vesnarinone on Peripheral Circulating Levels of Cytokines and Cytokine Receptors in Patients With Heart Failure : A Report From the Vesnarinone Trial. Chest
120: 453-459
[Abstract][Full Text]
Slawsky, M. T., Colucci, W. S., Gottlieb, S. S., Greenberg, B. H., Haeusslein, E., Hare, J., Hutchins, S., Leier, C. V., LeJemtel, T. H., Loh, E., Nicklas, J., Ogilby, D., Singh, B. N., Smith, W.
(2000). Acute Hemodynamic and Clinical Effects of Levosimendan in Patients With Severe Heart Failure. Circulation
102: 2222-2227
[Abstract][Full Text]
Tajima, M., Weinberg, E. O., Bartunek, J., Jin, H., Yang, R., Paoni, N. F., Lorell, B. H.
(1999). Treatment With Growth Hormone Enhances Contractile Reserve and Intracellular Calcium Transients in Myocytes From Rats With Postinfarction Heart Failure. Circulation
99: 127-134
[Abstract][Full Text]
Stevenson, L. W.
(1998). Inotropic Therapy for Heart Failure. NEJM
339: 1848-1850
[Full Text]
Lee, J.A, Allen, D.G
(1997). Calcium sensitisers: mechanisms of action and potential usefulness as inotropes. Cardiovasc Res
36: 10-20
[Full Text]
Torre-Amione, G., Kapadia, S., Lee, J., Durand, J.-B., Bies, R. D., Young, J. B., Mann, D. L.
(1996). Tumor Necrosis Factor-{alpha} and Tumor Necrosis Factor Receptors in the Failing Human Heart. Circulation
93: 704-711
[Abstract][Full Text]
Altschuld, R. A., Starling, R. C., Hamlin, R. L., Billman, G. E., Hensley, J., Castillo, L., Fertel, R. H., Hohl, C. M., Robitaille, P.-M. L., Jones, L. R., Xiao, R.-P., Lakatta, E. G.
(1995). Response of Failing Canine and Human Heart Cells to ß2-Adrenergic Stimulation. Circulation
92: 1612-1618
[Abstract][Full Text]
Swedberg, K., Wedel, H., Neely, D., Schwartz, A., Feldman, A. M., Bristow, M. R., Parmley, W. W., Packer, M.
(1994). Vesnarinone for Heart Failure. NEJM
330: 64-66
[Full Text]